This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
